---
title: "Why Moderna (MRNA) Stock Is Soaring Today – June 26, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290998418.md"
description: "Moderna (MRNA) stock surged nearly 15% to $69 following positive investor reaction to its Science Day updates, highlighting progress in cancer prevention, autoimmune diseases, and next-generation mRNA therapies. Key catalysts include the mRNA-4194 cancer program, MS candidate mRNA-1195, and strong FDA advisory panel support for its flu vaccine mRNA-1010. Despite a 42% monthly rally, analysts maintain a Hold consensus with an average price target of $45.42."
datetime: "2026-06-26T18:37:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290998418.md)
  - [en](https://longbridge.com/en/news/290998418.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290998418.md)
---

# Why Moderna (MRNA) Stock Is Soaring Today – June 26, 2026

Moderna (MRNA) stock jumped nearly 15% at one point on Friday to around $69 per share after investors reacted positively to the biotech firm's latest Science Day update. The move adds to a strong recent rally, with shares now up almost 42% over the past month. The rally suggests that investors are starting to look past Moderna's COVID vaccine business and focus more on its overall drug pipeline. The main reason for the optimism is that Moderna highlighted progress in cancer prevention, autoimmune disease, and next-generation mRNA medicines.

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

One of the biggest updates was mRNA-4194, the company's first cancer prevention program, which focuses on patients with Lynch syndrome. In addition, investors focused on mRNA-1195, Moderna's multiple sclerosis treatment candidate, which is expected to deliver early data later in 2026. Together, these programs show that Moderna has the potential to become a more diversified biotech company.

Meanwhile, Moderna also received a boost from its flu vaccine candidate, mRNA-1010. An FDA advisory panel voted 9-0 in favor of the vaccine for adults aged 50 and older, which raised hopes that regulators could approve it when the FDA makes its final decision on August 5, 2026. As a result, investors now have several potential catalysts to watch that aren't COVID-related.

## **Is MRNA Stock a Good Buy?**

Turning to Wall Street, analysts have a Hold consensus rating on MRNA stock based on two Buys, 19 Holds, and three Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average MRNA price target of $45.42 per share implies 31.2% downside risk.

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst](https://longbridge.com/en/news/290916339.md)
- [Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks](https://longbridge.com/en/news/290970667.md)
- [Moderna’s mRNA flu vaccine passes FDA AdCom, review underway](https://longbridge.com/en/news/290435765.md)
- [Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks](https://longbridge.com/en/news/290971983.md)
- [Stock Traders Buy High Volume of Moderna Call Options (NASDAQ:MRNA)](https://longbridge.com/en/news/290239041.md)